Individual Approach In Treatment Of Advanced Stomach Cancer

D Juraev, M Egamberdiev, S Khudayorov, N Tuyev


Background: To study efficiency of the combined treatment of advanced gastric cancer with inclusion Trastuzumab.

Material: We present the intermediate analysis of the use of target therapy with Trastuzumab in patients with a HER2-positive gastric cancer. Up to 01.10.2009y 118 patients have been tested for HER-2 expression, and in 24 gastric cancer patients it is revealed HER2-positive status of tumor. It is lead chemotherapy to all patients by the PLF regimen and Herceptin in doze 6 mg/kg once in 3 weeks (6 cycles). In control group in 26 patients it is lead only chemotherapy by the PLF regimen once in 3 weeks without addition Trastuzumab (6 cycles).

Results:  At the moment of the analysis of preliminary data, the median remission duration in compared groups has made 8.3 months, and 5.2 months, accordingly.

Conclusion: At advanced gastric cancer with high level HER-2 expression Trastuzumab increases frequency of objective effect and the median remission duration.


Stomach Cancer, Chemotherapy, Target Therapy

Full Text:



Aksel E. M. Condition of the oncological service to the population of Russia and the CIS countries in 2005 // Vestnik of N.N.Blohina of Russian Academy of Medical Science - 2007. - Т. 18, №2. – P. 8-51.

Davidov M. I., Aksel E. M. Death rate of the population of Russia and CIS countries from malignant tumors in 2005 // Vestnik of N.N.Blohina of Russian Academy of Medical Science, 2007. - Т.18, №2, - P. 90-120.

Karaseva V.V., Jerlov G.K., Lazerev A. F. The combined chemotherapy in disseminated stomach cancer // Russian ocological journal. - 2004. - №5. - P. 28-30.

Andrés Cervantes, Rosello S., Roda D. et al. The treatment of advanced gastric cancer: current strategies and future perspectives // ESMO Conference Lugano. Switzerland, (Lugano), 2008. Symposium lecture. - P. 103-107.

American Cancer Society. Global Cancer Facts and Figures 2007

Ohtsu A. J Gastroenterol 2008; 43:256-264

Hofmann M, Stoss O, Shi D, Buttner R, van d, V, Kim W et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52 (7):797-805.

Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51 (8):1371-1379.

Sasako M. Multimodal treatment of resectable gastric cancer: The Asian view // 10th World Congress on Gastrointestinal Cancer. Spain, (Barcelona), 2008. - P.153-161.

Van Cutsem et al. Abstract #7BA ECCO/ESMO 2009



  • There are currently no refbacks.

Print ISSN 1804-5804, Online ISSN 1804-9702

(c) 2018 CBU,o.p.s.